Norepinephrine reuptake inhibitor

Norepinephrine

Norepinephrine reuptake inhibitors (NRIs), also known as noradrenaline reuptake inhibitors (NARIs), are compounds that elevate the extracellular level of the neurotransmitter norepinephrine in the central nervous system by inhibiting its reuptake from the synaptic cleft into the presynaptic neuronal terminal. The drugs inhibit the class of neurotransmitter transporters known as norepinephrine transporters. They have virtually no action at other monoamine transporters.

List of NRIs

• Atomoxetine (Strattera^®)
• Reboxetine (Edronax^®)
• Viloxazine (Vivalan^®)
• Maprotiline (Ludiomil^®)
• Bupropion (Wellbutrin^®)
• Radafaxine (A drug related to Bupropion presently in clinical trials)

Strattera^® is available in the United States and is indicated by the Food and Drug Administration (FDA) for the treatment of ADD and ADHD. Off-label uses include the treatment of depression and anxiety.

Reboxetine, unavailable in the United States and Canada, has been found to be effective at combating depression.

Radafaxine, a potent metabolite of Bupropion, is currently being developed by GlaxoSmithKline.

See also

• adrenergic uptake inhibitor

de:Selektiver Noradrenalin-Wiederaufnahmehemmer